1. Home
  2. GKOS vs CELH Comparison

GKOS vs CELH Comparison

Compare GKOS & CELH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • CELH
  • Stock Information
  • Founded
  • GKOS 1998
  • CELH 2004
  • Country
  • GKOS United States
  • CELH United States
  • Employees
  • GKOS N/A
  • CELH N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • CELH Beverages (Production/Distribution)
  • Sector
  • GKOS Health Care
  • CELH Consumer Staples
  • Exchange
  • GKOS Nasdaq
  • CELH Nasdaq
  • Market Cap
  • GKOS 8.4B
  • CELH 7.5B
  • IPO Year
  • GKOS 2015
  • CELH N/A
  • Fundamental
  • Price
  • GKOS $102.04
  • CELH $33.65
  • Analyst Decision
  • GKOS Strong Buy
  • CELH Buy
  • Analyst Count
  • GKOS 13
  • CELH 17
  • Target Price
  • GKOS $161.54
  • CELH $45.53
  • AVG Volume (30 Days)
  • GKOS 1.0M
  • CELH 9.2M
  • Earning Date
  • GKOS 04-30-2025
  • CELH 05-06-2025
  • Dividend Yield
  • GKOS N/A
  • CELH N/A
  • EPS Growth
  • GKOS N/A
  • CELH N/A
  • EPS
  • GKOS N/A
  • CELH 0.45
  • Revenue
  • GKOS $383,481,000.00
  • CELH $1,355,630,000.00
  • Revenue This Year
  • GKOS $27.84
  • CELH $34.11
  • Revenue Next Year
  • GKOS $27.99
  • CELH $17.00
  • P/E Ratio
  • GKOS N/A
  • CELH $74.24
  • Revenue Growth
  • GKOS 21.85
  • CELH 2.85
  • 52 Week Low
  • GKOS $88.16
  • CELH $21.10
  • 52 Week High
  • GKOS $163.71
  • CELH $98.85
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 37.88
  • CELH 64.01
  • Support Level
  • GKOS $98.03
  • CELH $33.74
  • Resistance Level
  • GKOS $108.62
  • CELH $32.08
  • Average True Range (ATR)
  • GKOS 3.96
  • CELH 1.78
  • MACD
  • GKOS 1.87
  • CELH 0.51
  • Stochastic Oscillator
  • GKOS 47.86
  • CELH 79.66

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

About CELH Celsius Holdings Inc.

Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 96% of revenue concentrated in North America. Celsius' products contain natural ingredients and a metabolism-enhancing formulation, appealing to fitness and active lifestyle enthusiasts. The firm's portfolio includes its namesake Celsius Originals beverages, Celsius Essentials line (containing aminos), and Celsius On-the-Go powder packets. Celsius dedicates its efforts to branding and innovation, while it utilizes third parties for the manufacturing, packaging, and distribution of its products. In 2022, Celsius forged a 20-year distribution agreement with PepsiCo, which holds an 8.5% stake in the business.

Share on Social Networks: